Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Gains from Investment Securities (2017 - 2025)

Serina Therapeutics' Gains from Investment Securities history spans 9 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$7.3 million, changed N/A, while the annual FY2023 figure was -$1.1 million, 120.96% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$1.1 million at Serina Therapeutics, up from -$5.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $568000.0 in Q2 2021 and bottomed at -$5.6 million in Q1 2024.
  • The 5-year median for Gains from Investment Securities is $5000.0 (2022), against an average of -$544750.0.
  • The largest YoY upside for Gains from Investment Securities was 1522.86% in 2023 against a maximum downside of 22340.0% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $96000.0 in 2021, then tumbled by 94.79% to $5000.0 in 2022, then plummeted by 22340.0% to -$1.1 million in 2023, then crashed by 401.62% to -$5.6 million in 2024, then skyrocketed by 80.87% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Gains from Investment Securities are -$1.1 million (Q3 2025), -$5.6 million (Q1 2024), and -$1.1 million (Q4 2023).